I am a
Home I AM A Search Login

Papers of the Week


2020 Oct 21


Int J Mol Sci


21


20

Characterization of Neurons Expressing the Novel Analgesic Drug Target Somatostatin Receptor 4 in Mouse and Human Brains.

Authors

Kecskés A, Pohóczky K, Kecskés M, Varga ZV, Kormos V, Szőke É, Henn-Mike N, Fehér Máté, Kun J, Gyenesei A, Renner É, Palkovits M, Ferdinandy P, Ábrahám IM, Gaszner B, Helyes Z
Int J Mol Sci. 2020 Oct 21; 21(20).
PMID: 33096776.

Abstract

Somatostatin is an important mood and pain-regulating neuropeptide, which exerts analgesic, anti-inflammatory, and antidepressant effects via its Gi protein-coupled receptor subtype 4 (SST) without endocrine actions. SST is suggested to be a unique novel drug target for chronic neuropathic pain, and depression, as a common comorbidity. However, its neuronal expression and cellular mechanism are poorly understood. Therefore, our goals were (i) to elucidate the expression pattern of / mRNA, (ii) to characterize neurochemically, and (iii) electrophysiologically the /-expressing neuronal populations in the mouse and human brains. Here, we describe SST expression pattern in the nuclei of the mouse nociceptive and anti-nociceptive pathways as well as in human brain regions, and provide neurochemical and electrophysiological characterization of the SST-expressing neurons. Intense or moderate SST expression was demonstrated predominantly in glutamatergic neurons in the major components of the pain matrix mostly also involved in mood regulation. The SST agonist J-2156 significantly decreased the firing rate of layer V pyramidal neurons by augmenting the depolarization-activated, non-inactivating K current (M-current) leading to remarkable inhibition. These are the first translational results explaining the mechanisms of action of SST agonists as novel analgesic and antidepressant candidates.